Yihong Yao

Trials

Studies that name Yihong Yao as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:17 UTC. Open this list on ClinicalTrials.gov

• Ph2
  NCT07875413 · Prizloncabtagene Autoleucel (Prizlon-cel) for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Post FDA Approved CAR T-cell Therapy

  AbelZeta Inc. · not yet recruiting · Large B Cell Lymphoma, LBCL, Diffuse Large B Cell Lymphoma (DLBCL) · study director
• Ph1
  NCT07854483 · C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Systemic Sclerosis (SSc) Refractory to Standard Therapy

  AbelZeta Inc. · not yet recruiting · Systemic Sclerosis (SSc), Systemic Sclerosis, Systemic Sclerosis (Scleroderma) · study director
• Ph1/Ph2
  NCT07825389 · C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Progressive Multiple Sclerosis Refractory to Standard Therapy

  AbelZeta Inc. · not yet recruiting · Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Secondary Progress Multiple Sclerosis (SPMS) · study director

Grants

NIH projects from RePORTER, fetched 2026-11-12 08:17 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.